Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Structure and Function of Platelets

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sexual selection and ecological-demographical context drive the evolution of same-sex sexual behaviour.

Scientific reports·2026

Same author

Endothelial cell damage in patients with acute graft versus host disease receiving treatment with extracorporeal photopheresis.

Frontiers in immunology·2026

Same author

Comparison of CD34-positive cells enumeration using ADAMII image-based fluorescence cell counter with fluorescence flow cytometry.

Clinical chemistry and laboratory medicine·2026

Same author

Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: a retrospective study.

Therapeutic advances in neurological disorders·2026

Same author

Effect of Adhesive Type and Surface Preparation on the Debonding Behavior of Glass and Carbon Fiber Reinforced Epoxy Adhesive Joints.

Materials (Basel, Switzerland)·2026

Same author

Endothelial activation and damage associated with steroid-refractory aGVHD are counteracted by ruxolitinib.

Blood advances·2026

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Routine Screening Method for Microparticles in Platelet Transfusions

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

Platelet dose for prophylactic platelet transfusions.

Joan Cid¹, Miguel Lozano

¹Servei d' Hemoteràpia i Hemostasia, Hospital Clínic, C/. Villarroel, 170 08036 Barcelona, Spain. jcid@clinic.ub.es

Expert Review of Hematology

|November 19, 2010

Summary

This summary is machine-generated.

The dose of prophylactic platelet transfusions did not significantly impact bleeding in patients with hypoproliferative thrombocytopenia. This randomized controlled trial suggests platelet dose is not a critical factor for preventing bleeding in this patient group.

More Related Videos

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Related Experiment Videos

Last Updated: Jun 6, 2026

Routine Screening Method for Microparticles in Platelet Transfusions

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Area of Science:

Hematology
Transfusion Medicine
Clinical Trials

Background:

Platelet transfusion guidelines often lack evidence from large randomized controlled trials (RCTs).
The Effects of Prophylactic Platelet Dose on Transfusion Outcomes (PLADO) trial investigated the impact of varying prophylactic platelet doses.
Hypoproliferative thrombocytopenia poses significant bleeding risks, necessitating optimized transfusion strategies.

Discussion:

The PLADO trial found no significant difference in bleeding rates (WHO grade ≥2) across low, medium, and high prophylactic platelet dose groups.
This suggests that for patients with hypoproliferative thrombocytopenia and platelet counts ≤10 × 10⁹/l, the transfused platelet dose may not influence bleeding incidence.
Further research may explore other factors influencing bleeding in thrombocytopenic patients.

Key Insights:

Prophylactic platelet transfusion dose has no significant effect on bleeding incidence in patients with hypoproliferative thrombocytopenia.
Bleeding risk in thrombocytopenic patients is not significantly altered by low, medium, or high platelet transfusion doses.
The findings challenge the assumption that higher platelet doses confer greater protection against bleeding.

Outlook:

Future studies should focus on identifying optimal platelet transfusion triggers rather than doses.
Investigating non-dose-related factors, such as platelet function and patient-specific characteristics, is crucial.
Clinical practice guidelines may need revision based on evidence from trials like PLADO.